Thera-SAbDab

INFLIXIMAB

>   Structural Summary
TherapeuticInfliximab
TargetTNFA
Heavy ChainEVKLEESGGGLVQPGGSMKLSCVASGFIFSNHWMNWVRQSPEKGLEWVAEIRSKSINSATHYAESVKGRFTISRDDSKSAVYLQMTDLRTEDTGVYYCSRNYYGSTYDYWGQGTTLTVSS
Light ChainDILLTQSPAILSVSPGERVSFSCRASQFVGSSIHWYQQRTNGSPRLLIKYASESMSGIPSRFSGSGSGTDFTLSINTVESEDIADYYCQQSHSWPFTFGSGTNLEVK
100% seqID Fv Structure4g3y [Fvs: HL], 5vh3 [Fvs: AB, HL], 5vh4 [Fvs: AB, HL], 6ugs [Fvs: AB, HL], 6ugt [Fvs: AB, HL], 6ugu [Fvs: AB, HL], 6ugv [Fvs: AB, HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)NFD
Recorded Developmental Technologyna
INN Year Proposed1997
INN Year Recommended1998
Companies InvolvedCentocor, Janssen Biotech, Merck & Co, Mitsubishi Tanabe Pharma Corporation, National Jewish Medical and Research Center, Xian-Janssen
Conditions ApprovedAnkylosing spondylitis, Behcet's syndrome, Crohn's disease, Mucocutaneous lymph node syndrome, Plaque psoriasis, Psoriasis, Psoriatic arthritis, Rheumatoid arthritis, Ulcerative colitis
Conditions Activena
Conditions DiscontinuedBerylliosis, Hepatitis C, Pyoderma
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]